Professor Heiko Von der Leyen
MD,
Pharmacology, Internal Medicine, and Cardiology, University of Hamburg and Hannover Medical School.
Prof. Heiko von der Leyen, MD, was trained in Pharmacology, Internal Medicine, and Cardiology at University of Hamburg and Hannover Medical School. After 3 years of research at Stanford’s Falk Cardiovascular Research Center with focus on cardiovascular gene therapy he was appointed as junior faculty member at the Division of Cardiovascular Medicine of Stanford University from 1995 to 1996. From 1998 to 2005 Prof. von der Leyen served on several top management positions in the biotechnology industry with focus on the clinical development of advanced therapy medicinal products (tissue engineering, gene therapy, DNA medicine). In 2005, he became managing director (until 2020) of Hannover Clinical Trial Center GmbH (HCTC), an academic research organization with focus on clinical trial management services and early product development support, now incorporated into Hannover Medical School. In 2020 Prof. von der Leyen became Medical Director of Orgenesis, Inc, a biotech company focussing on cell and gene therapy. Prof. von der Leyen was a member of the Network Committee of ECRIN-ERIC, a pan-European clinical trials infrastructure organization, from 2014 to 2022.
He is a member of the Scientific Advisory Board of F-CRIN, the academic network for clinical research in France.